The global cancer biopsy market revenue was around US$ 23.18 billion in 2022 and is estimated to reach US$ 80.2 billion by 2031, growing at a compound annual growth rate (CAGR) of 14.8% during the forecast period from 2023 to 2031.
Cancer biopsy stands as a foundation in the oncology field. It provides invaluable insights into the characteristics, nature, and malignancies progression. This diagnostic procedure involves the tissue extraction or fluid sample from a suspicious lesion or mass, which is then analyzed under a microscope or via cutting-edge molecular techniques.
Market Driving Factors
The advent of liquid biopsy is one of the major factors driving the market growth. A liquid biopsy analyses the circulating DNA (cfDNA) from cells that are shed into the bloodstream by all tumors present in a patient with metastatic cancer. For instance, in June 2023, LabCorp disclosed the launch of liquid biopsy to detect cancer-related biomarkers. A new blood test from LabCorp could potentially assist cancer patients to begin the most effective treatments as soon as possible.
Novel therapeutic oncology and diagnostic technologies are penetrating not only across benchtop settings but are also achieving substantial demand in clinics. Many novel diagnostic technologies can alter oncology treatment and diagnosis. This has caught the attention of multiple regulators, care providers, and manufacturers, surge in investments in this area. This provides massive possibilities for cancer biopsy producers to establish their market existence as a requirement for effective and safe management of cancer burden becomes mandatory.
The high price of diagnosis to restrain the market expansion.
Regional Analysis
North America dominated the market in terms of the largest share and is estimated to maintain its dominance. This can be attributed to the cutting-edge healthcare infrastructure, extensive R&D activities the well-established healthcare system, and early adoption of advanced technologies. The region's high prevalence of cancer cases and surge in the geriatric population further contribute to its prominence. Furthermore, partnerships between key industry players and research institutions accelerate progress in biopsy technologies.
Asia-Pacific dominates the market during the projection period. This is due to the surge in healthcare infrastructure and increasing cancer prevalence. With a burgeoning population, there's a heightened demand for advanced diagnostic tools. Advanced diagnostic technologies are in high demand due to an expanding population. In addition, the number of cancer screenings has increased as a result of awareness campaigns and better access to healthcare services. Biopsies are becoming more and more common, which helps with accurate and timely cancer diagnosis.
Segmentation Insights
Type Insight
The liquid biopsy segment is projected to dominate the market. This is due to their capability to offer insights into diseases from both distant tumor and primary tumor sites. This process plays a key role in personalized medicine treatments, involving the recurrent sample of tumor markers to adapt treatment according to the patient's reaction. In addition, companies are integrating liquid biopsy with cutting-edge Artificial Intelligence (AI) technology for improved scrutiny of DNA mutations.
The tissue biopsy segment dominates the market in terms of revenue. It is generated in biopsy procedures, and it remains an important component of several cancer diagnostic applications. The reason for its constant popularity can be due to extensive research efforts that have been emphasized in evaluating the effectiveness and safety of this procedure. These endeavors have played a crucial role in maintaining the dominance of this segment in the market.
Product Type Insight
The kits and consumables segment dominates the market in terms of the largest share. These components play a vital role in many stages of biopsy procedures, and substantial investments by industry leaders have further improved their importance. Furthermore, the surge in several patients seeking efficient, precise, and rapid instruments and kits worldwide has significantly increased their demand.
Application Insight
The breast cancer segment dominates the market in terms of revenue. This is due to its high prevalence rate, especially affecting women. The alarming statistics highlight the essential requirement for timely and accurate diagnosis. Microscopic analysis of breast tissue, acquired through needle or surgical biopsies. It plays a necessary role in providing staging, definitive diagnoses, and characterizing the kind of breast cancer. Breast cancer's dominance in the biopsies market highlights how important biopsies are for the identification and treatment of this common and serious cancer.
Prominent Companies
Segmentation Outline
The global cancer biopsy market segmentation focuses on Type, Product Type, Application, and Region.
By Type
By Product Type
By Application
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL CANCER BIOPSY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: CANCER BIOPSY MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL CANCER BIOPSY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL CANCER BIOPSY MARKET, BY TYPE
5.1 OVERVIEW
5.2 LIQUID BIOPSY
5.3 TISSUE BIOPSY
5.4 OTHERS
6 GLOBAL CANCER BIOPSY MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 KITS AND CONSUMABLES
6.3 INSTRUMENTS
6.4 SERVICES
7 GLOBAL CANCER BIOPSY MARKET, BY APPLICATION
7.1 OVERVIEW
7.2 BREAST CANCER
7.3 CERVICAL CANCER
7.4 LUNG CANCER
7.5 COLORECTAL CANCER
7.6 OTHERS
8 GLOBAL CANCER BIOPSY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL CANCER BIOPSY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ABBOTT LABORATORIES
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 BECTON, DICKINSON AND COMPANY
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 BIO-RAD LABORATORIES INC
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 DANAHER CORPORATION
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 F. HOFFMANN-LA ROCHE LTD
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 HOLOGIC INC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 ILLUMINA INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 KONINKLIJKE PHILIPS N.V.
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 MYRIAD GENETICS INC
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 NEOGENOMICS INC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 QIAGEN N.V.
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 SIEMENS HEALTHINEERS AG
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 SYSMEX CORPORATION
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 THERMO FISHER SCIENTIFIC INC
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 VERACYTE INC
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved